Stanford Actionable Mutation Panel for Solid Tumors (STAMP)

Molecular Oncology

The STAMPT assay detects potentially clinically actionable mutations, as well as additional genes that are frequently mutated in cancers. The Stanford Actionable Mutation Panel for Solid Tumors (STAMPT) is a targeted next generation sequencing method that uses target enrichment to capture genomic regions of interest. The targeted sequencing approach and integrated bioinformatics workflow is optimized for ultra-deep sequencing of formalin fixed tumor biopsy tissue specimens. The workflow includes acoustic shearing of isolated genomic DNA, followed by efficient preparation of sequencing libraries and a target enrichment approach to capture genomic regions of interest for sequencing. The enrichment is done using custom designed libraries of capture oligonucleotides that target a specific set of genomic regions. This panel targets 197 genes, either in part or fully, with the genes selected on the basis of their known impact as actionable targets of existing and emerging anti-cancer therapies, their prognostic features, and/or their mutation recurrence frequency across patients with known cancer types. Pooled libraries are sequenced on an Illumina sequencing instrument. This test covers 197 genes, either in part or fully, at a minimum analytic detection limit of 5%.

The STAMPT assay detects potentially clinically actionable mutations, as well as additional genes that are frequently mutated in cancers. The Stanford Actionable Mutation Panel for Solid Tumors (STAMPT) is a targeted next generation sequencing method that uses target enrichment to capture genomic regions of interest. The targeted sequencing approach and integrated bioinformatics workflow is optimized for ultra-deep sequencing of formalin fixed tumor biopsy tissue specimens. The workflow includes acoustic shearing of isolated genomic DNA, followed by efficient preparation of sequencing libraries and a target enrichment approach to capture genomic regions of interest for sequencing. The enrichment is done using custom designed libraries of capture oligonucleotides that target a specific set of genomic regions. This panel targets 138 genes, either in part or fully, with the genes selected on the basis of their known impact as actionable targets of existing and emerging anti-cancer therapies, their prognostic features, and/or their mutation recurrence frequency across patients with known cancer types. Pooled libraries are sequenced on an Illumina sequencing instrument.

This test covers 138 genes, either in part or fully, at a minimum analytic detection limit of 5%.

Genomic positions are given in reference to the GRCh37 (hg19) assembly of the human genome.

81479